Incidence rate and causes of infection in Thai systemic sclerosis patients

International Journal of Rheumatic Diseases

Volumn 15, Issue 3, 2012, Pages 277-283

  Foocharoen, Chingching ^a   Siriphannon, Yada ^a   Mahakkanukrauh, Ajanee ^a   Suwannaroj, Siraphop ^a   Nanagara, Ratanavadee ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

Author keywords

Incidence rate; Infection; Opportunistic infection; Scleroderma; Systemic sclerosis

Indexed keywords

ADULT; AGED; ARTICLE; ASPIRATION PNEUMONIA; CANDIDIASIS; COHORT ANALYSIS; DIARRHEA; ESOPHAGUS MOTILITY; FEMALE; GASTROINTESTINAL INFECTION; HUMAN; INCIDENCE; INFECTION; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RISK FACTOR; SYSTEMIC SCLEROSIS; THAILAND;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; COMMUNICABLE DISEASES; ESOPHAGEAL MOTILITY DISORDERS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LINEAR MODELS; MALE; MIDDLE AGED; ODDS RATIO; OPPORTUNISTIC INFECTIONS; PNEUMONIA, ASPIRATION; PREVALENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SCLERODERMA, SYSTEMIC; THAILAND; TIME FACTORS; URINARY TRACT INFECTIONS;

EID: 84862536724     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/j.1756-185X.2012.01728.x     Document Type: Article

References (40)

1. Foocharoen C, Mahakkanukrauh A, Suwannaroj S, Nanagara R (2011) Spontaneous skin regression and predictors of skin regression in Thai scleroderma patients. Clin Rheumatol 30, 1235-40.
2. Domsic RT, Rodriguez-Reyna T, Lucas M, Fertig N, Medsger TA Jr (2011) Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann Rheum Dis 70, 104-9.
3. Apras S, Ertenli I, Ozbalkan Z et al. (2003) Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. Arthritis Rheum 48, 2256-61.
4. Calguneri M, Apras S, Ozbalkan Z et al. (2003) The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis. Clin Rheumatol 22, 289-94.
5. Miniati I, Valentini G, Cerinic MM (2009) Cyclophosphamide in systemic sclerosis: still in search of a "real life" scenario. Arthritis Res Ther 11, 103.
6. Pakas I, Ioannidis JPA, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachoyiannopoulos PG (2002) Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 29, 298-304.
7. Takehara K (2004) Treatment of early diffuse cutaneous systemic sclerosis patients in Japan by low-dose corticosteroids for skin involvement. Clin Exp Rheumatol 22(3 Suppl 33), S87-9.
8. Chen I-J, Tsai W-P, Wu Y-JJ et al. (2010) Infections in polymyositis and dermatomyositis: analysis of 192 cases. Rheumatology, 49, 2429-37.
9. Noël V, Lortholary O, Casassus P et al. (2001) Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus. Ann Rheum Dis 60, 1141-4.
10. Schmidt-Nowara WW (1984) Opportunistic infection, asthma and corticosteroid therapy. West J Med 140, 289-90.
11. Vargas PJ, King G, Navarra SV (2009) Central nervous system infections in Filipino patients with systemic lupus erythematosus. Int J Rheum Dis 12, 234-8.
12. Ginzler E, Diamond H, Kaplan D, Weiner M, Schlesinger M, Seleznick M (1978) Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus. Arthritis Rheum 21, 37-44.
13. Gladman DD, Hussain F, Ibañez D, Urowitz MB (2002) The nature and outcome of infection in systemic lupus erythematosus. Lupus 11, 234-9.
14. Hellmann DB, Petri M, Whiting-O'Keefe Q (1987) Fatal infections in systemic lupus erythematosus: the role of opportunistic organisms. Medicine (Baltimore) 66, 341-8.
15. Kang I, Park SH (2003) Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol 15, 528-34.
16. Hesselstrand R, Scheja A, Akesson A (1998) Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 57, 682-6.
17. Shalev T, Haviv Y, Segal E et al. (2006) Outcome of patients with scleroderma admitted to intensive care unit. A report of nine cases. Clin Exp Rheumatol 24, 380-6.
18. Tyndall AJ, Bannert B, Vonk M et al. (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69, 1809-15.
19. Alarcón GS (2006) Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis/dermatomyositis. Infect Dis Clin North Am 20, 849-75.
20. Marie I, Lahaxe L, Levesque H, Heliot P (2008) Pulmonary actinomycosis in a patient with diffuse systemic sclerosis treated with infliximab. QJM 101, 419-21.
21. Ferry AP, Font RL, Weinberg RS, Boniuk M, Schaffer CL (1988) Nocardial endophthalmitis: report of two cases studied histopathologically. Br J Ophthalmol 72, 55-61.
22. Walz BH, Crosby LA (1995) Mycobacterium avium-intracellulare infection of the knee joint. Case report. Am J Knee Surg 8, 35-7.
23. Gerster J-C, Duvoisin B, Dudler J, Berner IC (2004) Tenosynovitis of the Hands Caused by Mycobacterium kansasii in a patient with scleroderma. J Rheumatol 31, 2523-5.
24. Ward MM, Donald F (1999) Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum 42, 780-9.
25. Sripavatakul K, Foocharoen C (2011) Spontaneous pneumothorax from cryptococcal pneumonia in systemic sclerosis: a case report. J Med Case Reports 5, 309.
26. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23, 581-90.
27. LeRoy EC, Black C, Fleischmajer R et al. (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15, 202-5.
28. Denton C, Korn J (2003) Digital ulceration and critical digital ischaemia in scleroderma. Scleroderma Care Res 1, 12-6.
29. Korn JH, Mayes M, Matucci Cerinic M et al. (2004) Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50, 3985-93.
30. Alivernini S, De Santis M, Tolusso B et al. (2009) Skin ulcers in systemic sclerosis: determinants of presence and predictive factors of healing. J Am Acad Dermatol 60, 426-35.
31. Hooton TM. (1990) The epidemiology of urinary tract infection and the concept of significant bacteriuria. Infection 18(Suppl 2), S40-3.
32. Tishler M, Caspi D, Almog Y, Segal R, Yaron M (1992) Increased incidence of urinary tract infection in patients with rheumatoid arthritis and secondary Sjögren's syndrome. Ann Rheum Dis 51, 604-6.
33. Forbes A, Marie I (2009) Gastrointestinal complications: the most frequent internal complications of systemic sclerosis. Rheumatology (Oxford) 48(Suppl. 3), iii36-9.
34. Sallam H, McNearney TA, Chen JDZ (2006) Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment Pharmacol Ther 23, 691-712.
35. Khalifa M, Kaabia N, Bahri F, Ben Jazia E, Bouajina E, Omezzine Letaief A (2007) Infection in systemic lupus erythematosus. Med Mal Infect 37, 792-5.
36. Abraham DJ, Krieg T, Distler J, Distler O (2009) Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford) 48(Suppl. 3), iii3-7.
37. Kowal-Bielecka O, Landewé R, Avouac J et al. (2009) EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 68, 620-8.
38. Ng WL, Chu CM, Wu AKL, Cheng VCC, Yuen KY (2006) Lymphopenia at presentation is associated with increased risk of infections in patients with systemic lupus erythematosus. QJM 99, 37-47.
39. Mok CC, Lee KW, Ho CT, Lau CS, Wong RW (2000) A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology (Oxford) 39, 399-406.
40. Valentini G, Della Rossa A, Bombardieri S et al. (2001) European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 60, 592-8.